Search
Kite and Gilead @EHA25 Virtual
We are proud to support the first ever EHA25 Virtual congress. Please join us & leading experts to learn about the latest in cell therapies and COVID-19.
Read moreEHA-ISHBT Hematology Tutorial on Hematological Disorders
Dates: February 28-29, 2020
Location: Chandigarh, India
Chairs: N Varma, P Malhotra, J Gribben
Organized by: European Hematology Association (EHA) & Indian Society of Hematology and Blood Transfusion (ISHBT)
EHA will join ISHBT for a fourth time to organize the EHA-ISHBT Hematology Tutorial, this time in Chandigargh,…
Reduction of chemotherapy and PET-guided radiotherapy in advanced-stage Hodgkin lymphoma: the GHSG HD15 trial
Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor control and overall survival compared to previously used regimens. In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear.
Read moreNovel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing
Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.
Read moreHighlights of Past EHA (HOPE) Asia 2023
EHA joined forces with the Indian Society of Hematology & Blood Transfusion (ISHBT) to organize the 5th edition of the Highlights of Past EHA (HOPE) Asia 2023 meeting.
Read more